Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Pharma & Drugs
Share your love
Elon Musk’s Blindsight Implant Faces Skepticism from Researchers
Elon Musk recently announced on X that Blindsight, a cortical implant to restore vision, would have low resolution at first “but may ultimately exceed normal human vision.” Skepticism from University of Washington Research New research from the University of Washington…
Link Between Proteins in Tears and Pain After Eye Surgery
In a study published in the Journal of Proteome Research, researchers from Oregon Health & Science University (OHSU) have identified a connection between specific proteins found in patients’ tears and persistent pain experienced months after eye surgery. This discovery could…
New Insights on Retinoblastoma Treatment
Recent research presented at the Society of NeuroInterventional Surgery’s (SNIS) 21st Annual Meeting underscores significant improvements in treating retinoblastoma, a rare eye cancer affecting young children. The study reveals that advancements in treatment over the past 15 years have notably…
Nicox Concludes U.S. Recruitment for Phase 3 NCX 470 Trial
Nicox announced the recruitment and randomization of the final patient in the United States for its Denali Phase 3 trial of NCX 470. This milestone marks a significant step in evaluating the safety and efficacy of NCX 470 for patients…
Spryte’s nOCT Tech Gets FDA Breakthrough Device Designation
Spryte Medical announced that its Neuro Optical Coherence Tomography (nOCT) technology has been awarded Breakthrough Device Designation by the FDA. This designation highlights the potential of nOCT to revolutionize neurointervention and cerebrovascular treatment. FDA Breakthrough Device Designation The FDA’s Breakthrough…
Eyenovia and Senju Collaborate on Novel Dry Eye Treatment
Eyenovia, a leading ophthalmic company, announced a collaboration agreement with Senju Pharmaceutical to develop SJP-0035, a corneal epithelial wound healing candidate, using Eyenovia’s Optejet® dispensing technology for chronic dry eye disease treatment. Strategic Collaboration for Innovative Treatment Under the agreement,…
Oertli Receives FDA Clearance for Faros Anterior System
Oertli Instrumente AG announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its globally established Faros anterior cataract surgery system. This milestone underscores Oertli’s expansive global presence and unwavering commitment to delivering advanced and reliable…
Trial Results for Susvimo Show Sustained Efficacy in DME and DR
Genentech and Roche released compelling 2-year data from the phase 3 Pagoda and Pavilion studies evaluating Susvimo (ranibizumab injection) 100 mg/mL, marking a significant development in the treatment landscape for diabetic macular edema (DME) and diabetic retinopathy (DR). Reintroduction of…
Okyo Pharma’s Phase 2 Trial for Neuropathic Corneal Pain
Okyo Pharma announced its plan to initiate a phase 2 clinical trial for OK-101 in the treatment of neuropathic corneal pain (NCP), scheduled to begin in the third quarter of 2024. This one-year study follows promising results from preclinical animal…
NexThera Submits IND Application for NT-101 for Wet AMD
NexThera has officially submitted a Phase 1/2a Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for NT-101, an innovative non-invasive eye drop treatment targeting wet age-related macular degeneration (wet AMD). Proprietary Delivery Platform: Advancing Treatment…